Chronic Heart Failure

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

NCT00520780 | PHASE 3 | INTERVENTIONAL

This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.

48 Sites

456 Participants

Recruiting

18 Years to 45 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Research Sites

Buenos Aires,Argentina

Research Site

Bad Nauheim,Germany

Research Site

Berlin,Germany

Research Site

Göttingen,Germany

Research Site

Hannover,Germany

Research Sites

Heidelberg,Germany

Research Site

Herford,Germany

Research Site

Herne,Germany

Research Site

Kiel,Germany

Research Site

München,Germany

Research Site

Athens,Greece

Research Site

Heraklion,Greece

Research Site

Ascoli Piceno,Italy

Research Site

Pavia,Italy

Research Site

Rome,Italy

Research Site

Vicenza,Italy

Research Site

Stavanger,Norway

Research Site

Bialystok,Poland

Research Site

Krakow,Poland

Research Site

Opole,Poland

Research Site

Piotrkow Trybunalski,Poland

Research Site

Siedlce,Poland

Research Site

Torun,Poland

Research Site

Walbrzych,Poland

Research Sites

Warszawa,Poland

Research Site

Wloclawek,Poland

Research Site

Wroclaw,Poland

Research Site

Zabrze,Poland

Research Site

Brasov,Romania

Research Sites

Bucharest,Romania

Reserach Site

Craiova,Romania

Research Sites

Targu Mures,Romania

Reserach Sites

Moscow,Russian Federation

Research Sites

Novgorod,Russian Federation

Resarch Sites

St. Petersburg,Russian Federation

Research Site

Alicante,Spain

Research Sites

Barcelona,Spain

Research Site

Bilbao,Spain

Research Site

Madrid,Spain

Research Site

Valencia,Spain

Research Site

Dnipropetrovsk,Ukraine

Research Site

Donetsk,Ukraine

Research Site

Kharkiv,Ukraine

Research Sites

Kiev,Ukraine

Research Site

Lviv,Ukraine

Research Site

Mykolayiv,Ukraine

Research Site

Odessa,Ukraine

Research Site

Zaporozhye,Ukraine

Study Eligibility Criteria

Inclusion Criteria

* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
* Left ventricular ejection fraction (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
* Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
* Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%

Exclusion Criteria

* History of acquired iron overload.
* Known active infection, clinically significant bleeding, active malignancy.
* Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST)
* Anaemia due to reasons other than iron deficiency
* Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).
* History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
* Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
* Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months.
* Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.

Additional Studies

Additional studies can be found at ClinicalTrials.gov